{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:25:57Z","timestamp":1790040357466,"version":"4.0.1"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapsed or refractory pediatric patients with B\u2010acute lymphoblastic leukemia (B\u2010ALL) have high rates of toxicities and relapse, and novel therapy is needed. We present a case of a 5\u2010year\u2010old male child with high\u2010risk B\u2010ALL that was refractory to several re\u2010induction regimens. He was put into minimal residual disease\u2010negative remission after re\u2010induction with chemotherapy plus overlapping rituximab, inotuzumab ozogamicin, and blinatumomab, termed mini\u2010hyper\u2010CVD (cyclophosphamide, vincristine, and dexamethasone) plus CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab). This regimen was well tolerated, and he received his transplant and engrafted with no significant infections, toxicities, or sinusoidal obstruction syndrome. This is the first reported use of a condensed sequential immunotherapy\/chemotherapy regimen in a pediatric leukemia patient.<\/jats:p>","DOI":"10.1002\/pbc.29939","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T04:38:45Z","timestamp":1661747925000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mini\u2010hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B\u2010acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"70","author":[{"given":"David","family":"McCall","sequence":"first","affiliation":[{"name":"Department of Pediatrics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roth","sequence":"additional","affiliation":[{"name":"Department of Pediatrics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Nunez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506153322407"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8018"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1636"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"LBA\u20101\u2010LBA","DOI":"10.1182\/blood-2019-132435","article-title":"A randomized phase 3 trial of blinatumomab vs. chemotherapy as post\u2010reinduction therapy in high and intermediate risk (HR\/IR) first relapse of B\u2010acute lymphoblastic leukemia (B\u2010ALL) in children and adolescents\/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children's Oncology Group Study AALL1331","volume":"134","author":"Brown PA","year":"2019","journal-title":"Blood"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112269"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.034"},{"key":"e_1_2_7_8_1","first-page":"S124","article-title":"Rationale and design of total therapy study XV for newly diagnosed childhood acute lymphoblastic leukemia","volume":"83","author":"Pui CH","year":"2004","journal-title":"Ann Hematol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62002-8"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03736"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33469"},{"key":"e_1_2_7_12_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5\u00d77.pdf. Accessed April 16 2018."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2918"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24987"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28136"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605085"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2380"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32116"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_7_21_1","unstructured":"FDA Label for Blinatumomab. 2014.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125557lbl.pdf. Accessed May 2022"},{"key":"e_1_2_7_22_1","unstructured":"Package insert for BESPONSA (inotuzumab ozogamicin). 2017.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf. Accessed May 2022"},{"key":"e_1_2_7_23_1","unstructured":"Drug Label: RITUXAN\u00ae (rituximab) injection for intravenous use. 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5465lbl.pdf. Accessed May 2022"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.29939","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T05:56:05Z","timestamp":1692510965000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.29939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,28]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/pbc.29939"],"URL":"https:\/\/doi.org\/10.1002\/pbc.29939","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,28]]},"assertion":[{"value":"2022-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29939"}}